Treatment of insulin resistance and disorders associated therewith
AssigneeUniversitetet I Oslo
InventorsEili Tranheim Kase, Arild Chr. Rustan, Gunn Hege Thoresen, Hilde Irene Nebb, Pål Rongved, Jo Klaveness, Bjarne Brudeli
Life of this patent
Estimating the term…
Abstract
The present invention provides the use of an LXR antagonist, or a physiologically-acceptable pro-drug therefor, in the manufacture of a medicament for combating insulin resistance or a disorder associated therewith. Further provided is a compound being an ester or carbamate of a hydroxycholesterol, a pharmaceutical composition of such a compound or its use in therapy.
Claims21
A method of treating a subject to combat insulin resistance or a disorder associated therewith comprising administering 22-S-hydroxycholesterol, or a physiologically-acceptable pro-drug therefor to said subject.
-8. (canceled)
-24. (canceled)
A product comprising 22-S-hydroxycholesterol or a physiologically acceptable prodrug therefor, and a second agent effective for combating insulin resistance or a disorder associated therewith as a combined preparation for simultaneous, separate or sequential use in combating insulin resistance or a disorder associated therewith.
Dependencies are inferred from the claim text.